Compare · ARGX vs BCAB
ARGX vs BCAB
Side-by-side comparison of argenx SE (ARGX) and BioAtla Inc. (BCAB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and BCAB operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $16.17B, about 48.6x BCAB ($332.6M).
- ARGX has hit the wire 2 times in the past 4 weeks while BCAB has been quiet.
- ARGX has more recent analyst coverage (25 ratings vs 8 for BCAB).
- Company
- argenx SE
- BioAtla Inc.
- Price
- $780.08-1.00%
- $5.06-9.24%
- Market cap
- $16.17B
- $332.6M
- 1M return
- +11.90%
- -
- 1Y return
- +25.72%
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2020
- News (4w)
- 2
- 0
- Recent ratings
- 25
- 8
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
BioAtla Inc.
BioAtla, Inc., a biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of various cancers. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and other tumor types. It also develops BA3021, a CAB ADC for NSCLC and Melanoma; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. The company was founded in 2007 and is based in San Diego, California.
Latest ARGX
- SEC Form 6-K filed by argenx SE
- argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP
- SEC Form 6-K filed by argenx SE
- argenx announces Annual General Meeting of Shareholders on May 6, 2026
- SEC Form 20-F filed by argenx SE
- SEC Form 6-K filed by argenx SE
- argenx upgraded by Deutsche Bank
- SEC Form 6-K filed by argenx SE
- argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline
- SEC Form 6-K filed by argenx SE
Latest BCAB
- BioAtla Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form S-8 filed by BioAtla Inc.
- BioAtla Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 10-K filed by BioAtla Inc.
- BioAtla Announces Share Consolidation
- BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
- BioAtla Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders
- Chief Medical Officer Sievers Eric was granted 240,000 shares, increasing direct ownership by 67% to 598,705 units (SEC Form 4)
- Chief Executive Officer Short Jay M Phd was granted 430,000 shares, increasing direct ownership by 19% to 2,659,603 units (SEC Form 4)
- Chief Financial Officer Vasquez Christian was granted 240,000 shares, increasing direct ownership by 83% to 530,196 units (SEC Form 4)